Skip to main content

Table 1 ANOVA-based F-statistic and relative validity for CKD-specific and generic PRO measures across clinically-defined groups (N = 453)

From: Using the bootstrap to establish statistical significance for relative validity comparisons among patient-reported outcome measures

PRO measure Dialysis Pre-dialysis stage 3-5 Transplant rb(total) F-statistic RV 95% CI c
(n = 206) (n = 113) (n = 134)
Mean (SD) r a Mean (SD) r a Mean (SD) r a
CKD-specific              
QDIS-CKD              
 CAT-5 39.83 (22.17) 1 16.19 (21.51) 1 19.25 (21.63) 1 1 57.43** 1 -
 Static-6 39.18 (22.86) 0.91 16.86 (21.84) 0.96 19.60 (21.29) 0.93 0.94 50.15** 0.87 (0.72-1.03)
 Static-34 35.93 (21.23) 0.93 14.90 (20.05) 0.96 18.71 (20.52) 0.95 0.95 48.01** 0.84 (0.71-0.97)
KDQOL              
 Burden 48.83 (26.81) -0.60 76.62 (24.76) -0.73 68.21 (28.90) -0.77 -0.74 44.46** 0.77 (0.53-1.09)
 Symptoms 71.95 (16.23) -0.57 80.58 (15.80) -0.65 80.03 (15.96) -0.66 -0.65 15.11** 0.26 (0.13-0.44)
 Effects 63.41 (21.92) -0.54 84.38 (17.59) -0.79 77.86 (20.18) -0.73 -0.71 43.95** 0.77 (0.52-1.10)
Generic              
SF-12              
 PF 37.06 (10.75) -0.52 45.38 (11.12) -0.57 44.88 (10.69) -0.65 -0.63 31.12** 0.54 (0.32-0.85)
 RP 38.00 (9.41) -0.65 45.12 (9.78) -0.61 45.83 (9.91) -0.63 -0.69 34.12** 0.59 (0.38-0.89)
 BP 43.19 (11.67) -0.47 46.71 (11.27) -0.53 47.10 (11.66) -0.49 -0.50 5.84** 0.10 (0.02-0.22)
 GH 39.08 (11.19) -0.47 41.99 (10.11) -0.51 43.71 (10.93) -0.56 -0.52 7.79** 0.14 (0.04-0.28)
 VT 45.72 (9.25) -0.44 46.40 (10.15) -0.46 48.35 (9.93) -0.48 -0.44 3.04* 0.05 (0.00-0.15)
 SF 42.75 (11.79) -0.65 47.81 (11.25) -0.61 47.83 (10.78) -0.60 -0.64 11.02** 0.19 (0.07-0.34)
 RE 44.59 (11.64) -0.52 48.39 (10.05) -0.49 48.39 (9.76) -0.42 -0.51 7.01** 0.12 (0.03-0.25)
 PCS 36.60 (10.29) -0.54 43.49 (10.37) -0.56 44.08 (10.72) -0.66 -0.64 26.61** 0.46 (0.27-0.74)
 MCSd 49.74 (10.38) -0.49 50.42 (9.57) -0.45 50.55 (9.94) -0.32 -0.40 0.32 - -
 MHd 49.85 (10.39) -0.43 50.71 (10.25) -0.49 50.31 (9.95) -0.33 -0.38 0.26 - -
  1. *Significant at the 0.05 level ** Significant at the 0.01 level.
  2. Abbreviations: ANOVA analysis of variance, RV relative validity, CKD chronic kidney disease, PRO patient-reported outcome, QDIS-CKD quality-of-life disease impact scale for chronic kidney disease, KDQOL kidney disease quality-of-life, SF-12 Short Form 12, PF physical functioning, RP role physical, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role emotional, PCS physical component summary, MCS mental component summary, MH mental health.
  3. a r refers to the correlation of scores between each comparison measure and the reference measure (QDIS-CKD CAT-5) within each clinical group.
  4. b r(total) refers to the correlation of scores between each comparison measure and the reference measure (QDIS-CKD CAT-5) for the total group (N = 453).
  5. c The 95% confidence interval of the RV was derived from the original data using the bootstrap BCa interval.
  6. d The F-statistics for SF-12 MCS and MH are small and non-significant ( p-values of 0.73 and 0.77 separately), therefore their RVs were not computed and excluded from significance test.